Senators grilled Novo Nordisk CEO Lars Jørgensen Tuesday at a hearing over the costs of Ozempic, Wegovy and similar weight loss drugs. The drugs have risen in popularity for diabetic patients and others looking to combat obesity since they were approved,

CEO Lars Fruergaard Jorgensen, has revealed that their diabetes medication and often hailed as a “miracle” weight loss drug, Ozempic will soon be eligible for U.S. government price negotiations, potentially within the next year.

Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of blockbuster drugs Ozempic and Wegovy when he appears Tuesday before a congressional committee led by Senator Bernie Sanders: It’s the middlemen.

U.S. Senator Bernie Sanders is set to question Novo Nordisk CEO Lars Jorgensen on Tuesday over the drugmaker's prices for its popular weight-loss and diabetes medicines that can cost Americans more than $1,

The announcement counters one of the most common talking points pharmaceutical companies cite when they argue against reducing list prices of their drugs, which is that cuts would lead to narrower coverage because pharmacy middlemen known as PBMs are incentivized to include expensive drugs on formularies because they lead to larger rebates.

The chief executive of the company behind Ozempic and Wegovy blamed insurers and middlemen for the high costs of weight-loss drugs in the U.S. during a congressional testimony on Tuesday. Why it matters: Lars Fruergaard Jørgensen,

Is Ozempic and Wegovy maker Novo Nordisk helping Americans save taxpayer money or ripping them off? The company's CEO is scheduled to testify on Capitol Hill Tuesday.

CEO Lars Fruergaard Jørgensen will shift the blame for the high prices of the company’s popular weight loss treatments to drug middlemen and the ‘complex’ U.S. health care system today during a committee hearing in Congress.